Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats

Pharmacology

Volumn 82, Issue 4, 2008, Pages 304-309

  Soni, Hitesh ^a   Sharma, Ajay ^a   Bhatt, Shvetank ^a   Jain, Mukul R ^a   Patel, Pankaj R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Carboxypeptidase inhibitor; TAFI; Thrombin activatable fibrinolysis inhibitor; Thrombosis; Tissue plasminogen activator

Indexed keywords

CARBOXYPEPTIDASE; CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; ENZYME PRECURSOR; FERRIC CHLORIDE; FIBRIN; LYSINE; PLANT EXTRACT; SODIUM CHLORIDE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FIBRINOLYSIS; MALE; NONHUMAN; POTATO; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; BLEEDING TIME; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; PARTIAL THROMBOPLASTIN TIME; PLANT PROTEINS; PROTEASE INHIBITORS; PROTHROMBIN TIME; RATS; RATS, WISTAR; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 53949125385     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165118     Document Type: Article

References (23)

1. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D: Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991;266:21833-21838.
2. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-16608.
3. Klement P, Liao P, Bajzar L: A novel approach to arterial thrombolysis. Blood 1999;94:2735-2743.
4. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
5. Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995;96:2534-2538.
6. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME: A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-27181.
7. Christensen U: C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen. FEBS Lett 1985;182:43-46.
8. Fleury V, Angles-Cano E: Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991;30:7630-7638.
9. Hosaka Y, Takahashi Y, Ishii H: Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998;79:371-377.
10. Sakharov DV, Plow EF, Rijken DC: On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997;272:14477-14482.
11. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J: Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002;109:101-110.
12. Marx PF: Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004;11:2335-2348.
13. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF: Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996;93:1328-1330.
14. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P: An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000;98:333-342.
15. Muto Y, Suzuki K, Sato E, Ishii H: Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003;461:181-189.
16. Minnema MC, Friederich PW, Levi M, dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H: Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998;101:10-14.
17. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN: Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003;101:4844-4846.
18. Kurz KD, Main BW, Sandusky GE: Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990;60:269-280.
19. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP: Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998;97:1002-1008.
20. Hashimoto M, Yamashita T, Oiwa K, Watanabe S, Giddings JC, Yamamoto J: Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 2002;87:110-113.
21. Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S, Ishii H: Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004;309:607-615.
22. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA: Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost 2006;4:403-410.
23. Bird E, Tamura J, Bostwick JS, Steinbacher TE, Stewart A, Liu Y, Baumann J, Feyen J, Tamasi J, Schumacher WA: Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 2007;120:549-558.